The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC

The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC

The treatment of non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs) has been proven to induce lasting tumor remission. Screening suitable populations for immunotherapy through predictive markers is an important approach to improving the clinical benefits of patients. Evidenc...

Full description

Bibliographic Details
Main Authors:	Xiaohua Li, Yuntao Wang, Xuebing Li, Gang Feng, Sheng Hu, Yifeng Bai
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-07-01
Series:	Frontiers in Immunology
Subjects:	NOTCH signaling non-small cell lung cancer immune checkpoint inhibitors tumor microenvironment immunogenicity
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.638763/full

Similar Items

Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients
by: Zhe Wang, et al.
Published: (2021-08-01)

Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors
by: Zihui Li, et al.
Published: (2020-11-01)

Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy
by: Junyu Long, et al.
Published: (2021-07-01)

The regulation of immune checkpoints by the hypoxic tumor microenvironment
by: Min Hu, et al.
Published: (2021-05-01)

Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
by: Derya Kabacaoglu, et al.
Published: (2018-08-01)

Pan‐cancer analysis identifies TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatment
by: Tao Jiang, et al.
Published: (2020-06-01)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
by: Florent Petitprez, et al.
Published: (2020-05-01)

Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies
by: I-Tsu Chyuan, et al.
Published: (2021-03-01)

Calreticulin couples with immune checkpoints in pancreatic cancer
by: Xing Huang, et al.
Published: (2020-03-01)

Crosstalk Between the Tumor Microenvironment and Cancer Cells: A Promising Predictive Biomarker for Immune Checkpoint Inhibitors
by: Xiaoying Li, et al.
Published: (2021-10-01)

Analysis of Tumor Microenvironment Characteristics in Bladder Cancer: Implications for Immune Checkpoint Inhibitor Therapy
by: Xingyu Chen, et al.
Published: (2021-04-01)

ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment
by: Ruibin Yi, et al.
Published: (2020-08-01)

Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
by: Jingjing Duan, et al.
Published: (2018-09-01)

Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity
by: Nicole E. Scharping, et al.
Published: (2016-12-01)

Notch pathway is involved in the suppression of colorectal cancer by embryonic stem cell microenvironment
by: Lan G, et al.
Published: (2019-04-01)

The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment
by: Patrizia Leone, et al.
Published: (2021-05-01)

Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
by: Rachael M. Zemek, et al.
Published: (2020-02-01)

Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors
by: Yang Wen, et al.
Published: (2021-06-01)

Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors
by: Qi J, et al.
Published: (2021-02-01)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
by: Vera Petrova, et al.
Published: (2020-03-01)

Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment
by: Antonino Carbone, et al.
Published: (2019-06-01)

Influence of Estrogen on the NSCLC Microenvironment: A Comprehensive Picture and Clinical Implications
by: Tanner Smida, et al.
Published: (2020-02-01)

The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
by: Bonnie L. Russell, et al.
Published: (2021-06-01)

Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies
by: Josée Golay, et al.
Published: (2020-05-01)

Survival prediction and response to immune checkpoint inhibitors: A prognostic immune signature for hepatocellular carcinoma
by: Ying Xu, et al.
Published: (2021-01-01)

Hypoxia-Driven Immune Escape in the Tumor Microenvironment
by: Alyssa Vito, et al.
Published: (2020-04-01)

Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer
by: Anqi Lin, et al.
Published: (2021-03-01)

Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma
by: Mengshi Li, et al.
Published: (2021-07-01)

Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors
by: Kerstin Kapp, et al.
Published: (2019-12-01)

Notch Signaling as a Regulator of the Tumor Immune Response: To Target or Not To Target?
by: Mahnaz Janghorban, et al.
Published: (2018-07-01)

Identification of a prognostic immune signature for cervical cancer to predict survival and response to immune checkpoint inhibitors
by: Si Yang, et al.
Published: (2019-12-01)

Immune Checkpoint Inhibitors in Human Glioma Microenvironment
by: Amina Ghouzlani, et al.
Published: (2021-07-01)

The N6-Methyladenosine-Modified Pseudogene HSPA7 Correlates With the Tumor Microenvironment and Predicts the Response to Immune Checkpoint Therapy in Glioblastoma
by: Rongrong Zhao, et al.
Published: (2021-07-01)

Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity
by: Wei Xie, et al.
Published: (2019-11-01)

Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades
by: Jun-Yan Li, et al.
Published: (2021-02-01)

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors
by: Yu Chen, et al.
Published: (2020-09-01)

Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors
by: Magalie Dosset, et al.
Published: (2020-07-01)

Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC
by: Jialin Qu, et al.
Published: (2020-07-01)

NKAP alters tumor immune microenvironment and promotes glioma growth via Notch1 signaling
by: Guangyan Gu, et al.
Published: (2019-07-01)

Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities
by: Antonio Santaniello, et al.
Published: (2019-09-01)